SCHEMBL1734512

SCHEMBL1734512

COCCCNc1nc(C(N)=O)cc(-c2cccc(OC)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 2/20 0.48
MAPT P10636 3/20 0.47
ADORA1 P30542 4/20 0.46
ADORA2A P29274 4/20 0.46
IRAK4 Q9NWZ3 1/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PIM1 P11309 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
ADORA3 P0DMS8 2/20 0.44
ADORA2B P29275 2/20 0.44
IKBKB O14920 1/20 0.44
LTB4R Q15722 1/20 0.43
PRKDC P78527 1/20 0.43
ATR Q13535 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734123 0.87 VCP (0.51) VCPMAPTADORA1ADORA2AIRAK4
SCHEMBL1734170 0.84 VCP (0.51) VCPMAPTADORA1ADORA2AIRAK4
SCHEMBL1733359 0.83 ADORA1 (0.50) VCPMAPTADORA1ADORA2AIRAK4
SCHEMBL1734129 0.83 VCP (0.48) VCPMAPTADORA1ADORA2AIRAK4
SCHEMBL1734639 0.82 VCP (0.70) VCP
SCHEMBL1734586 0.81 KDM4E (0.66) VCPMAPTADORA1ADORA2AHPGD
SCHEMBL1733528 0.77 ADORA1 (0.60) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1734655 0.77 NPC1 (0.58) VCPMAPTHPGDNPC1TP53
SCHEMBL1733560 0.74 KDM4E (0.53) MAPTADORA1ADORA2AHPGDNPC1
SCHEMBL1733546 0.74 KDM4E (0.52) MAPTADORA1ADORA2AIRAK4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 VCP 224/4885MAPT 4639/4885ADORA1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.